
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOYk9mUWhhb1k4Y3NtYzB1QzgyVXRybE5HQVlXTVZLcmtQY1l1R0hPTjFnT3VWVEZqNWhUOTgtUlVvVWpLVV9Ib3NmSUFnM2FBenJxN0RtZzgyZUlZM2txLWlMOXFBWjNxUmxxeDgtS0xUb25xYlFYOEtWcnpIcmF2b2xDeHZkZ3pvbERuR09MOElsYWxMajdReW9yNWRfZlN4UmVHNl9kYjB2ajRXQW9iUnRPcklLTGs2OG5jS1pBZWJWNmlYZURuMElYT0ZnOGJrSFMyN01lRDJXSlZYRVA1NGg2Tmc1WU13c0E?oc=5" target="_blank">Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials</a>&nbsp;&nbsp;<font color="#6f6f6f">springermedicine.com</font>
